Nicolas Girard, MD, PhD, Institut Curie, Paris, France, discusses the notable findings from two studies presented in the plenary session at the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. The first study, Phase III ADRIATIC (NCT03703297), showcases impressive data on small cell lung cancer (SCLC), highlighting significant survival benefits with durvalumab consolidation therapy, a breakthrough after 30 years of stagnation in this field. The second study, the Phase III LAURA trial (NCT03521154), focuses on EGFR-positive, locally advanced lung cancer, demonstrating the efficacy of TKI consolidation post-chemotherapy. This underscores the importance of early exposure to inhibitors in oncogene-addicted tumors, not only in metastatic and adjuvant settings but also potentially as neoadjuvant treatment. These findings raise important questions about sequencing treatments and could be extended to other oncogene-addicted tumors such as ALK-positive lung cancer, and possibly RET, HER2, and BRAF mutations. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть